An application of the C∗ concept in predicting the topical efficacy of finite dose acyclovir in the treatment of cutaneous HSV-1 infections in hairless mice

[1]  Seung-Ho Choi,et al.  Controlled (trans) dermal delivery of an antiviral agent (acyclovir). I: An in vivo animal model for efficacy evaluation in cutaneous HSV-1 infections , 1990 .

[2]  K. Knutson,et al.  Effects of long-term hydration leading to the development of polar channels in hairless mouse stratum corneum. , 1989, Journal of pharmaceutical sciences.

[3]  B. Domin,et al.  Acyclovir transport into human erythrocytes. , 1988, The Journal of biological chemistry.

[4]  B. W. Barry,et al.  Limitations of hairless mouse skin as a model for in vitro permeation studies through human skin: hydration damage. , 1988, The Journal of investigative dermatology.

[5]  J. Ansell,et al.  The acute oral toxicity and primary ocular and dermal irritation of selected N-alkyl-2-pyrrolidones. , 1988, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[6]  S. W. Kim,et al.  Preformulation of an Ara-A transdermal delivery system: Membrane fabrication and characterization , 1987 .

[7]  J. C. Martin,et al.  1-(2-Deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-ethyluracil. A highly selective antiherpes simplex agent. , 1987, Journal of Medicinal Chemistry.

[8]  R. Dix,et al.  Effect of antiviral agents on replication of herpes simplex virus type 1 in brain cultures , 1986, Antimicrobial Agents and Chemotherapy.

[9]  A. Al-Hasani,et al.  Susceptibility of HSV strains from patients with genital herpes treated with various formulations of acyclovir. , 1986, The Journal of antimicrobial chemotherapy.

[10]  S. Spruance,et al.  Efficacy of topical treatment for herpes simplex virus infections: predictions from an index of drug characteristics in vitro. , 1986, The Journal of infectious diseases.

[11]  G. Flynn,et al.  Influence of 1-dodecylazacycloheptan-2-one (Azone) on the topical therapy of cutaneous herpes simplex virus type 1 infection in hairless mice with 2',3'-di-O-acetyl-9-beta-D-arabinofuranosyladenine and 5'-O-valeryl-9-beta-D-arabinofuranosyladenine. , 1985, Journal of pharmaceutical sciences.

[12]  D. Smee,et al.  Comparative anti-herpesvirus activities of 9-(1,3-dihydroxy-2-propoxymethyl)guanine, acyclovir, and two 2'-fluoropyrimidine nucleosides. , 1985, Antiviral research.

[13]  L. Corey,et al.  In vitro sensitivity to acyclovir in genital herpes simplex viruses from acyclovir-treated patients. , 1983, The Journal of infectious diseases.

[14]  G. Elion.  The biochemistry and mechanism of action of acyclovir. , 1983, The Journal of antimicrobial chemotherapy.

[15]  D. Parris,et al.  Herpes simplex virus variants restraint to high concentrations of acyclovir exist in clinical isolates , 1982, Antimicrobial Agents and Chemotherapy.

[16]  P. de Miranda,et al.  Metabolism of acyclovir in virus-infected and uninfected cells , 1981, Antimicrobial Agents and Chemotherapy.

[17]  G. Elion,et al.  Inhibition of cellular alpha and virally induced deoxyribonucleic acid polymerases by the triphosphate of acyclovir , 1980, Antimicrobial Agents and Chemotherapy.

[18]  G. Elion,et al.  Inhibition of herpes simplex virus-induced DNA polymerase activity and viral DNA replication by 9-(2-hydroxyethoxymethyl)guanine and its triphosphate , 1979 .

[19]  H. Schaeffer,et al.  Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[20]  E. Kern,et al.  Herpesvirus hominis infection in newborn mice. I. An experimental model and therapy with iododeoxyuridine. , 1973, The Journal of infectious diseases.